Takeda Pharmaceutical Company Limited announced its official sponsorship of Berlin Marathon 2007 to be held on Sunday September 30, which will expand Takeda's support for marathon to Europe, as Takeda has been sponsoring Hokkaido Marathon in Japan for 13 years while started its sponsorship for The LaSalle Bank Chicago Marathon last year.
Read more ...
Prix Galien USA Names HUMIRA Best Biotechnology Product
Abbott (NYSE: ABT), a leader in the treatment of autoimmune diseases, has received the 2007 Galen Prize for Best Biotechnology Product for HUMIRA (R) (adalimumab), the first approved fully human antibody. HUMIRA is approved for use in the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe Crohn's disease.
Read more ...
Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Bayer Schering Pharma AG, Germany, and Genzyme Corporation, USA, today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).
Read more ...
Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer
Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with advanced gastric cancer. Additionally, data from phase I studies provide information on the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies in the treatment of hormone-refractory prostate cancer (HRPC) and advanced breast cancer.
Read more ...
Start of the TALENT Study - a Unique Antihypertensive Study in Europe
Bayer Schering Pharma AG announces the kick-start of the TALENT study, a multicenter "STudy EvALuating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control", which will examine two of its major antihypertensive brands in combination with each other.
Read more ...
Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX™
Nycomed and NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced that they have entered into a definitive agreement which licenses to Nycomed the rights to develop and commercialize GATTEX™ (teduglutide) outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders.
Read more ...
FDA Accepts sNDA for Expanded Use of Angiomax®
The Medicines Company (NASDAQ: MDCO) announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental new drug application (sNDA) for a modified dosing regimen of Angiomax® (bivalirudin) for the treatment of acute coronary syndromes (ACS), specifically in patients with unstable angina or non-segment elevation myocardial infarction (NSTEMI).
Read more ...